A role for low hepatic copper concentrations in nonalcoholic fatty liver disease

American Journal of Gastroenterology

Volumn 105, Issue 9, 2010, Pages 1978-1985

  Aigner, Elmar ^a   Strasser, Michael ^b   Haufe, Heike ^b   Sonnweber, Thomas ^c   Hohla, Florian ^a   Stadlmayr, Andreas ^a   Solioz, Marc ^d   Tilg, Herbert ^c   Patsch, Wolfgang ^b   Weiss, Guenter ^c   Stickel, Felix ^d   Datz, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; INSULIN;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; CONTROLLED STUDY; DIET RESTRICTION; FATTY LIVER; FEMALE; HEMOCHROMATOSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER DISEASE; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; ANIMAL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DIET; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HEPATITIS C; INFLAMMATION; LIVER; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ADULT; ANIMALS; COPPER; DIET; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FIBROSIS; HEMOCHROMATOSIS; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HUMANS; INFLAMMATION; INSULIN; LIVER; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC;

EID: 77956338865     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.170     Document Type: Article

References (41)

1. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007; 23: 193-198
2. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837-847
3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (Baltimore, Md) 2006; 43: S99-112
4. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008; 24: 320-327
5. Cornier MA, Dabelea D, Hernandez TL et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822
6. Al-Othman AA, Rosenstein F, Lei KY. Copper deficiency alters plasma pool size, percent composition and concentration of lipoprotein components in rats. J Nutr 1992; 122: 1199-1204
7. Al-Othman AA, Rosenstein F, Lei KY. Copper deficiency increases in vivo hepatic synthesis of fatty acids, triacylglycerols, and phospholipids in rats. Proc Soc Exp Biol Med 1993; 204: 97-103
8. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat 2005; 2: 46-53
9. Prohaska JR, Geissler J, Brokate B et al. Copper, zinc-superoxide dismutase protein but not mRNA is lower in copper-deficient mice and mice lacking the copper chaperone for superoxide dismutase. Exp Biol Med (Maywood) 2003; 228: 959-966
10. Schuschke DA, Adeagbo AS, Patibandla PK et al. Cyclooxygenase-2 is upregulated in copper-deficient rats. Inflammation 2009; 32: 333-339
11. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z et al. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-707
12. Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-1163
13. Aigner E, Theurl I, Haufe H et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008; 135: 680-688
14. Aigner E, Theurl I, Theurl M et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008; 87: 1374-1383
15. Nose Y, Kim BE, Th iele DJ. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab 2006; 4: 235-244
16. Wei Y, Rector RS, Th yfault JP et al. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14: 193-199
17. Seshadri V, Fox PL, Mukhopadhyay CK. Dual role of insulin in transcriptional regulation of the acute phase reactant ceruloplasmin. J Biol Chem 2002; 277: 27903-27911
18. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Technical Report 992. WHO: Geneva, Switzerland, 1999
19. Galdston M, Levytska V, Schwartz MS et al. Ceruloplasmin. Increased serum concentration and impaired antioxidant activity in cigarette smokers, and ability to prevent suppression of elastase inhibitory capacity of alpha 1-proteinase inhibitor. Am Rev Respir Dis 1984; 129: 258-263
20. Sobbrio GA, Granata A, Granese D et al. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen. Clin Exp Obstet Gynecol 1991; 18: 43-45
21. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474
22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (Baltimore, Md) 1996; 24: 289-293
23. Tipoe GL, Ho CT, Liong EC et al. Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD). Histol Histopathol 2009; 24: 1161-1169
24. Danzeisen R, Araya M, Harrison B et al. How reliable and robust are current biomarkers for copper status? Br J Nutr 2007; 98: 676-683
25. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-1698
26. Ferenci P, Steindl-Munda P, Vogel W et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's disease. Clin Gastroenterol Hepatol 2005; 3: 811-818
27. Ouyang X, Cirillo P, Sautin Y et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999
28. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-717
29. Moschen AR, Tilg H. Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2008; 11: 620-625
30. Klevay LM. Cardiovascular disease from copper deficiency\a history. J Nutr 2000; 130: 489S-92S
31. Klevay LM. Dietary copper and risk of coronary heart disease. Am J Clin Nutr 2000; 71: 1213-1214
32. Bakalli RI, Pesti GM, Ragland WL et al. Dietary copper in excess of nutritional requirement reduces plasma and breast muscle cholesterol of chickens. Poult Sci 1995; 74: 360-365
33. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22 (Suppl 1): S20-7
34. Zeng H, Saari JT, Johnson WT. Copper deficiency decreases complex IV but not complex I, II, III, or V in the mitochondrial respiratory chain in rat heart. J Nutr 2007; 137: 14-18
35. Fromenty B, Robin MA, Igoudjil A et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30: 121-138
36. Chitturi S, Weltman M, Farrell GC et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology (Baltimore, Md) 2002; 36: 142-149
37. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-1133
38. Lalor PF, Faint J, Aarbodem Y et al. The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis 2007; 27: 173-193
39. Engstrom G, Hedblad B, Stavenow L et al. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Th romb Vasc Biol 2004; 24: 1498-1502
40. Gitlin JD. Transcriptional regulation of ceruloplasmin gene expression during inflammation. J Biol Chem 1988; 263: 6281-6287
41. Olivares M, Mendez MA, Astudillo PA et al. Present situation of biomarkers for copper status. Am J Clin Nutr 2008; 88: 859S-62S